Logo

Merck and Eisai Provide P-III (LEAP-002) Trial Update of Keytruda (pembrolizumab) + Lenvima (lenvatinib) for Unresectable Hepatocellular Carcinoma

Share this
Merck and Eisai Provide P-III (LEAP-002) Trial Update of Keytruda (pembrolizumab) + Lenvima (lenvatinib) for Unresectable Hepatocellular Carcinoma

Merck and Eisai Provide P-III (LEAP-002) Trial Update of Keytruda (pembrolizumab) + Lenvima (lenvatinib) for Unresectable Hepatocellular Carcinoma

Shots:

  • The P-III (LEAP-002) trial evaluating Keytruda + Lenvima vs Lenvima monothx. in a ratio (1:1) in 794 patients with uHCC
  • The trial failed to meet its dual 1EPs of OS & PFS in patients with uHCC, trends toward improvement in OS & PFS but these results did not meet statistical significance per the pre-specified statistical plan, m-OS of the Lenvima monothx. was longer than that observed in prior reported clinical trials. The safety profile of Keytruda + Lenvima was consistent with prior reported data on the combination
  • The results are expected to be presented at an upcoming medical conference. Keytruda is currently approved as monothx. in the US, EU, China, Japan & other countries globally for the same indication

Ref: Businesswire | Image: Merck

 

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions